149 related articles for article (PubMed ID: 32968863)
1. Post-treatment CT LI-RADS categories: predictors of overall survival in hepatocellular carcinoma post bland transarterial embolization.
Ormiston WEL; Yarmohammadi H; Lobaugh S; Schilsky J; Katz SS; LaGratta M; Velayati S; Zheng J; Capanu M; Do RKG
Abdom Radiol (NY); 2021 Aug; 46(8):3738-3747. PubMed ID: 32968863
[TBL] [Abstract][Full Text] [Related]
2. Reproducibility of LI-RADS treatment response algorithm for hepatocellular carcinoma after locoregional therapy.
Abdel Razek AAK; El-Serougy LG; Saleh GA; Shabana W; Abd El-Wahab R
Diagn Interv Imaging; 2020 Sep; 101(9):547-553. PubMed ID: 32253141
[TBL] [Abstract][Full Text] [Related]
3. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy.
Shropshire EL; Chaudhry M; Miller CM; Allen BC; Bozdogan E; Cardona DM; King LY; Janas GL; Do RK; Kim CY; Ronald J; Bashir MR
Radiology; 2019 Jul; 292(1):226-234. PubMed ID: 31038409
[TBL] [Abstract][Full Text] [Related]
4. LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI.
Pirasteh A; Sorra EA; Marquez H; Sibley RC; Fielding JR; Vij A; Rich NE; Arroyo A; Yopp AC; Khatri G; Singal AG; Yokoo T
Abdom Radiol (NY); 2021 Aug; 46(8):3708-3716. PubMed ID: 33755735
[TBL] [Abstract][Full Text] [Related]
5. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
[No Abstract] [Full Text] [Related]
6. Performance of LI-RADS version 2018 CT treatment response algorithm in tumor response evaluation and survival prediction of patients with single hepatocellular carcinoma after radiofrequency ablation.
Zhang Y; Wang J; Li H; Zheng T; Jiang H; Li M; Song B
Ann Transl Med; 2020 Mar; 8(6):388. PubMed ID: 32355832
[TBL] [Abstract][Full Text] [Related]
7. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
[TBL] [Abstract][Full Text] [Related]
8. Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization.
Bartnik K; Podgórska J; Rosiak G; Korzeniowski K; Rowiński O
Abdom Radiol (NY); 2022 Jan; 47(1):115-122. PubMed ID: 34581927
[TBL] [Abstract][Full Text] [Related]
9. LI-RADS Version 2018 Treatment Response Algorithm: Diagnostic Performance after Transarterial Radioembolization for Hepatocellular Carcinoma.
Yoon J; Lee S; Shin J; Kim SS; Kim GM; Won JY
Korean J Radiol; 2021 Aug; 22(8):1279-1288. PubMed ID: 33987991
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the LI-RADS treatment response algorithm in hepatocellular carcinoma after trans-arterial chemoembolization.
Kierans AS; Najjar M; Dutruel SP; Gavlin A; Chen C; Lee MJ; Askin G; Halazun KJ
Clin Imaging; 2021 Dec; 80():117-122. PubMed ID: 34303189
[TBL] [Abstract][Full Text] [Related]
11. Liver imaging reporting and data system (LI-RADS) v2018: Reliability and agreement for assessing hepatocellular carcinoma locoregional treatment response.
Abdelrahman AS; Ekladious MEY; Badran EM; Madkour SS
Diagn Interv Imaging; 2022 Nov; 103(11):524-534. PubMed ID: 35787988
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Performance of LI-RADS Treatment Response Algorithm for Hepatocellular Carcinoma: Adding Ancillary Features to MRI Compared with Enhancement Patterns at CT and MRI.
Park S; Joo I; Lee DH; Bae JS; Yoo J; Kim SW; Lee JM
Radiology; 2020 Sep; 296(3):554-561. PubMed ID: 32692297
[TBL] [Abstract][Full Text] [Related]
13. The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma.
Chaudhry M; McGinty KA; Mervak B; Lerebours R; Li C; Shropshire E; Ronald J; Commander L; Hertel J; Luo S; Bashir MR; Burke LMB
Radiology; 2020 Feb; 294(2):320-326. PubMed ID: 31845843
[TBL] [Abstract][Full Text] [Related]
14. Per-patient Negative Predictive Value of the CT and MRI Liver Imaging Reporting and Data System Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma.
Hassan OT; Behr SC; Ohliger MA; Fowler KJ; Gill RM; Fidelman N; Mehta N; Choi HH
Radiology; 2023 Dec; 309(3):e222776. PubMed ID: 38112541
[TBL] [Abstract][Full Text] [Related]
15. Added Value of CT Arterial Subtraction Images in Liver Imaging Reporting and Data System Treatment Response Categorization for Transcatheter Arterial Chemoembolization-Treated Hepatocellular Carcinoma.
Huh J; Kim B; Lee JH; Won JH; Kim J; Kwon Y; Kim JK
Invest Radiol; 2021 Feb; 56(2):109-116. PubMed ID: 33405431
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of Liver Imaging Reporting and Data System locoregional treatment response criteria: a systematic review and meta-analysis.
Gupta P; Bansal A; Das GC; Kumar-M P; Chaluvashetty SB; Bhujade H; Gulati A; Kalra N
Eur Radiol; 2021 Oct; 31(10):7725-7733. PubMed ID: 33786656
[TBL] [Abstract][Full Text] [Related]
18. Liver Imaging-Reporting and Data System treatment response algorithm predicts postsurgical recurrence in locoregional therapy-treated hepatocellular carcinoma.
Youn SY; Kim B; Kim DH; Choi HJ; Sung PS; Choi JI
Eur Radiol; 2022 Sep; 32(9):6270-6280. PubMed ID: 35348864
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of Arterial Subtraction in Applying Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm to Gadoxetic Acid-Enhanced MRI.
Youn SY; Kim DH; Choi JI; Choi MH; Kim B; Shin YR; Oh SN; Rha SE
Korean J Radiol; 2021 Aug; 22(8):1289-1299. PubMed ID: 34047507
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
[No Abstract] [Full Text] [Related]
[Next] [New Search]
